Ascendis Pharma A/S announced an extension of its exclusive distribution agreement with Er-Kim, an international pharmaceutical company. This expanded partnership will commercialize three of Ascendis's rare endocrinology disease treatments in additional Eurasian countries. The therapies included in this agreement are SKYTROFA, YORVIPATH, and TransCon CNP.
Under the extended agreement, Er-Kim is now appointed as the exclusive representative for Ascendis's endocrinology rare disease portfolio in Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. This builds upon the initial agreement announced in January 2024, which covered Central and Eastern Europe and Turkey. The expansion aims to address significant unmet medical needs and broaden patient access to these innovative treatments across a wider geographical area.
The collaboration leverages Er-Kim's expertise in commercializing novel therapies in international markets, supporting Ascendis Pharma's commitment to making a meaningful difference in patients' lives. This strategic move is expected to contribute to the global uptake and revenue growth of Ascendis's key products by tapping into previously underserved regions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.